ATHA Stock Summary and Trading Ideas (Athira Pharma | NASDAQ:ATHA)

Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.

Athira Pharma trades on the NASDAQ stock market under the symbol ATHA.

As of September 18, 2024, ATHA stock price declined to $0.46 with 841,268 million shares trading.

ATHA has a beta of 5.76, meaning it tends to be more sensitive to market movements. ATHA has a correlation of 0.16 to the broad based SPY ETF.

ATHA has a market cap of $17.75 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, ATHA stock traded as high as $16.65 and as low as $.46.

The top ETF exchange traded funds that ATHA belongs to (by Net Assets): VTI, VXF, SMLF, DFAT, IWC.

ATHA has underperformed the market in the last year with a price return of -77.1% while the SPY ETF gained +27.8%. ATHA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -82.2% and -83.6%, respectively, while the SPY returned +2.9% and +1.7%, respectively.

ATHA support price is $.46 and resistance is $.52 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ATHA stock will trade within this expected range on the day.